Formosa Pharmaceuticals Announces New Partnership for Ocular Treatment
Taiwan-based Formosa Pharmaceuticals has recently revealed an exciting exclusive licensing agreement with Samil Pharmaceuticals, enhancing their commitment to improving ocular care. This agreement grants Samil the rights to commercialize clobetasol propionate ophthalmic suspension, a groundbreaking treatment designed for managing inflammation and pain after ocular surgeries in South Korea.
About the Innovative Treatment
The patented formulation, known as APP13007, features a 0.05% concentration of clobetasol propionate, a highly effective corticosteroid. Utilizing Formosa Pharma’s proprietary APNT® nanoparticle formulation platform, APP13007 offers a more convenient dosing schedule—only twice daily for 14 days—while ensuring rapid relief from inflammation and pain. This efficiency is particularly important given that South Korea performs a remarkable number of ocular surgeries each year, with almost 800,000 cataract procedures alone.
Benefits of APP13007
In a survey involving 100 ophthalmic surgeons, APP13007 demonstrated a significant impact, revealing that approximately 80% of patients experienced complete pain resolution within four days after surgery. The overall safety profile is also commendable, with an adverse event rate of less than 2%. These results highlight why surgeons are keen on prescribing this innovative medication.
Strengthening Strategic Partnerships
Erick Co, Formosa’s President and CEO, expressed enthusiasm over the expanded collaboration, noting the shared vision of serving patients undergoing ocular surgeries in Korea. Samil Pharmaceuticals, known for its leadership in ophthalmology, is poised to ensure that APP13007 achieves its maximum potential in the market.
Looking Ahead
Seungbum Huh, Chairman of Samil Pharmaceuticals, stated that this agreement marks a significant step forward for their partnership. Following the establishment of a contract manufacturing organization agreement for APP13007, this licensing deal aims to deliver a high-quality treatment option to healthcare professionals and patients in Korea, following successful global trials and FDA approval.
About Formosa Pharmaceuticals, Inc.
Formosa Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on innovative therapies in ophthalmology and oncology. Their groundbreaking APNT® technology, which facilitated the development of APP13007, enhances the delivery of challenging drug formulations for effective treatments. This commitment to efficacy and patient care is central to their mission.
About Samil Pharmaceuticals Co., Ltd.
Samil Pharmaceutical Co., Ltd. has a rich history, founded in 1947 and based in Seoul, South Korea. Their expertise spans various therapeutic areas, including ophthalmology, and they have established a strong global presence through subsidiaries and partnerships around the world. The company is dedicated to improving healthcare through innovative products and state-of-the-art facilities.
Frequently Asked Questions
What is the main focus of the partnership between Formosa and Samil?
The partnership between Formosa Pharmaceuticals and Samil Pharmaceuticals focuses on the commercialization of APP13007, aimed at treating inflammation and pain post-ocular surgery in South Korea.
What is APP13007?
APP13007 is a patented ophthalmic suspension containing clobetasol propionate, a superpotent corticosteroid designed for effective treatment following ocular surgeries.
How does the dosing schedule of APP13007 work?
APP13007 is administered twice daily for a duration of 14 days, providing a simple and straightforward regimen for patients.
What are the clinical outcomes associated with APP13007?
Clinical data indicates that about 80% of patients reported being pain-free within four days post-surgery, accompanied by a low adverse event rate of less than 2%.
What does the agreement between Formosa and Samil signify for patients?
This agreement signifies a commitment to enhance treatment options for patients undergoing ocular surgeries, ensuring they have access to innovative and effective therapies.
